Vyvanse (lisdexamfetamine dimesylate; Shire) is now available as chewable tablets for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged ≥6 years and for moderate to severe binge eating disorder in adults.

The Food and Drug Administration (FDA) initially approved the chewable tablet formulation in January 2017. Vyvanse capsules can be substituted with the chewable tablets on a mg per mg basis.

Related Articles

Vyvanse, a central nervous system (CNS) stimulant, is a prodrug of dextroamphetamine. Amphetamines are noncatecholamine sympathomimetic amines with CNS stimulant activity. Amphetamines block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.

Vyvanse is currently available as 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, and 70mg strength capsules in 100-count bottles. The chewable tablets are available in 10mg, 20mg, 30mg, 40mg, 50mg, and 60mg strengths in 100-count bottles.

For more information call (800) 828-2088 or visit VyvansePro.com.